Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia. It also offers MIN-117, a compound that has completed Phase IIa clinical trial for the treatment of patients suffering from major depressive disorder (MDD); and seltorexant, which is in Phase IIb clinical trial for treating insomnia and MDD. The company' preclinical stage product is MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of the MIN-117 compound and roluperidone worlwide, excluding Asia; and co-development and license agreement with Janssen Pharmaceutica, N.V. for the development of seltorexant. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was founded in 2007 and is based in Waltham, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NERV
CUSIPN/A
Phone617-600-7373
Debt
Debt-to-Equity RatioN/A
Current Ratio22.32
Quick Ratio22.32
Price-To-Earnings
Trailing P/E Ratio-8.29
Forward P/E Ratio-6.37
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.40 per share
Price / Book2.60
Profitability
EPS (Most Recent Fiscal Year)($1.08)
Net Income$-31,520,000.00
Net MarginsN/A
Return on Equity-36.80%
Return on Assets-25.50%
Miscellaneous
Employees12
Outstanding Shares38,770,000
Market Cap$327.64 million
Minerva Neurosciences (NASDAQ:NERV) Frequently Asked Questions
What is Minerva Neurosciences' stock symbol?
Minerva Neurosciences trades on the NASDAQ under the ticker symbol "NERV."
How were Minerva Neurosciences' earnings last quarter?
Minerva Neurosciences Inc (NASDAQ:NERV) announced its earnings results on Thursday, August, 2nd. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.06. View Minerva Neurosciences' Earnings History.
When is Minerva Neurosciences' next earnings date?
What price target have analysts set for NERV?
1 brokers have issued twelve-month price targets for Minerva Neurosciences' shares. Their forecasts range from $19.00 to $19.00. On average, they expect Minerva Neurosciences' share price to reach $19.00 in the next twelve months. This suggests a possible upside of 114.7% from the stock's current price. View Analyst Price Targets for Minerva Neurosciences.
What is the consensus analysts' recommendation for Minerva Neurosciences?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Minerva Neurosciences in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Minerva Neurosciences.
Who are some of Minerva Neurosciences' key competitors?
Some companies that are related to Minerva Neurosciences include Biohaven Pharmaceutical (BHVN), Wave Life Sciences (WVE), Esperion Therapeutics (ESPR), TherapeuticsMD (TXMD), Eagle Pharmaceuticals (EGRX), Athenex (ATNX), Lexicon Pharmaceuticals (LXRX), Intra-Cellular Therapies (ITCI), Vanda Pharmaceuticals (VNDA), Endocyte (ECYT), Zai Lab (ZLAB), Karyopharm Therapeutics (KPTI), CytomX Therapeutics (CTMX), Rhythm Pharmaceuticals (RYTM) and Retrophin (RTRX).
Who are Minerva Neurosciences' key executives?
Minerva Neurosciences' management team includes the folowing people:
- Dr. Rémy Luthringer, Exec. Chairman & CEO (Age 57)
- Mr. Geoffrey Robin Race, Exec. VP, CFO, Chief Bus. Officer & Company Sec. (Age 57)
- Dr. Michael Davidson, Chief Medical Officer (Age 68)
- Mr. Richard Russell, Pres (Age 54)
- Mr. Joseph Reilly, Sr. VP & COO (Age 43)
Has Minerva Neurosciences been receiving favorable news coverage?
Headlines about NERV stock have trended somewhat negative recently, Accern Sentiment Analysis reports. Accern ranks the sentiment of press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Minerva Neurosciences earned a media and rumor sentiment score of -0.11 on Accern's scale. They also gave press coverage about the biopharmaceutical company an impact score of 47.02 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future. View Recent Headlines for Minerva Neurosciences.
Who are Minerva Neurosciences' major shareholders?
Minerva Neurosciences' stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.63%), Highland Capital Management LP (4.41%), Millennium Management LLC (2.37%), Dimensional Fund Advisors LP (1.01%), Northpointe Capital LLC (0.66%) and Renaissance Technologies LLC (0.45%). Company insiders that own Minerva Neurosciences stock include Frederick W Ahlholm, Geoff Race, Joseph H Reilly, Marc D Beer, Mark S Levine and Remy Luthringer. View Institutional Ownership Trends for Minerva Neurosciences.
Which institutional investors are selling Minerva Neurosciences stock?
NERV stock was sold by a variety of institutional investors in the last quarter, including Highland Capital Management LP, DAFNA Capital Management LLC and Alps Advisors Inc.. Company insiders that have sold Minerva Neurosciences company stock in the last year include Frederick W Ahlholm, Geoff Race, Joseph H Reilly and Remy Luthringer. View Insider Buying and Selling for Minerva Neurosciences.
Which institutional investors are buying Minerva Neurosciences stock?
NERV stock was bought by a variety of institutional investors in the last quarter, including Northpointe Capital LLC, BlackRock Inc., Renaissance Technologies LLC, Dimensional Fund Advisors LP, Russell Investments Group Ltd., Alpine Woods Capital Investors LLC, Handelsbanken Fonder AB and Millennium Management LLC. View Insider Buying and Selling for Minerva Neurosciences.
How do I buy shares of Minerva Neurosciences?
Shares of NERV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Minerva Neurosciences' stock price today?
One share of NERV stock can currently be purchased for approximately $8.85.
How big of a company is Minerva Neurosciences?
Minerva Neurosciences has a market capitalization of $327.64 million. The biopharmaceutical company earns $-31,520,000.00 in net income (profit) each year or ($1.08) on an earnings per share basis. Minerva Neurosciences employs 12 workers across the globe.
How can I contact Minerva Neurosciences?
Minerva Neurosciences' mailing address is 1601 TRAPELO ROAD SUITE 286, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 617-600-7373 or via email at [email protected]
MarketBeat Community Rating for Minerva Neurosciences (NASDAQ NERV)
MarketBeat's community ratings are surveys of what our community members think about Minerva Neurosciences and other stocks. Vote "Outperform" if you believe NERV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NERV will underperform the S&P 500 over the long term. You may vote once every thirty days.
